Despite diffıcult conditions throughout West Africa during the height of the Ebola outbreak, the European and American teams conducting diagnostic procedures during the crisis provided an important and effective component of the broader clinical and public health interventions that brought the outbreak under control.
The bulk of that diagnostic testing relied on RT-PCR. At fırst, most of the clinical specimens were sent to Europe or the United States (US) for analysis. However, as the outbreak expanded and the numbers of specimens grew exponentially, arrangements were made to conduct those diagnostic analyses locally, often in makeshift laboratories-"'hot labs' under tin roofs," as one on-site participant noted. Indeed, specimens were "hot," meaning biologically dangerous, and ambient temperatures were plenty hot, playing havoc with instruments designed for use in air-conditioned settings.
A European consortium sent two mobile laboratory units to Africa, with one of them deployed to Guinea in March 2014, according to Stephan Guenther of the Bernhard Nocht Institute for Tropical Medicine in Hamburg, Germany. At fırst, local offıcials "built a nice tent for us," he says. Later, a "more stable structure" was made available for ongoing diagnostic work, some of it done inside glove boxes-a challenging undertaking because of the high numbers of samples being analyzed.
While PCR analysis played a lead role during the outbreak, genomic sequencing also was brought into playnot to diagnose individual cases but to determine whether and in what ways the Ebola virus might be changing during the course of the outbreak, according to Jeffrey Kugelman of the U.S. Army Medical Research Institute of Infectious Diseases at Fort Detrick in Frederick, Md. At fırst sequencing analysis was done with samples sent to U.S. and European labs. However, because shipping logistics were cumbersome and speedier results were deemed critical, a good part of that work shifted to Africa, he says.
The early focus of genomic sequencing was to determine whether changes in viral sequence might lead the virus to be resistant to experimental therapeutics, Kugelman says. Now sequencing data also are being scrutinized to determine whether genomic changes might affect diagnostic probes or, more broadly, might help to explain other features of the outbreak.
Other, simpler rapid diagnostics are already available or soon will be. Early this year, Food and Drug Administration (FDA) offıcials issued an emergency use authorization to Corgenix of Broomfıeld, Colo., for its ReEBOV antigen rapid test for detecting antibodies to Ebola in blood samples. "This is a preliminary assay for testing patients to support triage," says Robert Cross of theUniversityofTexasMedicalBranch, Galveston, who is part of a larger consortium helping to develop and evaluate such tests. The results from such testing need to be "validated with PCR," he adds. Unlike PCR, however, the antigen tests are easy to use, yield results within minutes, and hold up well to heat and other adverse conditions.
Another whole-blood test system being developed and which is funded by the National Institute of Allergy and Infectious Disease, like PCR, amplifıes nucleic acid to detect the Ebola virus, in New three-dimensional images show bacteria so tiny that 150 of them could fıt into a single Escherichia coli cell. "These ultrasmall bacteria are a subset of microbial life on Earth that we know almost nothing about," says Jill Banfıeld at the University of California, Berkeley. She and her colleagues used two-and three-dimensional cryogenic transmission electron microscopy to gather information about the cell walls, morphology, and volume of these ultrasmall bacteria. Details appeared 27 February 2015 in Nature Communications (doi:10.1038/ncomms7372).
The ultrasmall bacteria were discovered in groundwater fıltered through standard 0. Some of these miniaturized microbial cells are dumbbell-shaped, suggesting the cells are dividing or budding, according to Banfıeld. Their metabolic options appear to be limited-for example, the cells undergo no signifıcant tricarboxylic acid cycle and lack components of the electron transport chain, making it likely that they scavenge building blocks from other microbes. "We have no clues to the functions of 50% of their genes," she says.
Metagenomic and other DNAbased analysis match the ultrasmall bacteria to the WWE3, OP11, and OD1 candidate phyla, whose other members are found in diverse environments, including hot springs, permafrost, mines, oceans, peat bogs, and subsurface ecosystems. In a forthcoming report, Banfıeld and her colleagues estimate that bacterial members of those phyla are "part of a larger group of small organisms that may comprise up to 15% of all bacteria on Earth," she says. Investigations of these enigmatic microbes could lead to insights about how such microbial communities affect water, climate, and other ecosystems.
The miniaturized size of these newly recognized bacteria may help them "to attain a greater surface-tovolume ratio, which may be handy for taking up scarce resources in oligotrophic environments," says Moselio Schaechter, visiting scholar at the University of California, San Diego, and distinguished professor emeritus of Tufts University in Boston, Mass.
Because these ultrasmall bacteria live under fairly stable conditions, "they need not carry extra genes for adap-
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Recent national and international developments involving microbiology and related science policy matters include:
• The Obama administration in April announced measures to protect the U.S. population against detrimental health effects arising due to climate change, including changes in vector-borne diseases and waterand food-related issues.
• The White House Office of Science and Technology Policy in March said it was seeking comments (the comment period is now closed) on the impact of federal Select Agent Regulations on research and national security and that it would study the comments to identify "gaps and challenges concerning those regulations." • Biomedical research funded through the U.S. National Institutes of Health (NIH) generates nearly $106 million in downstream R&D for each $100 million invested through NIH grants on average, according to the report, "Patents as Proxies Revisited: NIH Innovation 2000 to 2013," released by the Battelle Memorial Institute of Columbus, Ohio, last March.
• Several members of the US Congress in January introduced the Promise for Antibiotics and Therapeutics for Health (PATH) Act, which seeks to establish a new approval pathway for antibiotics.
